RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Clinical trials for RECURRENT ADULT ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ADULT ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT ADULT ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists unleash engineered virus to hunt down blood cancers
Disease control Recruiting nowThis early-stage trial is testing a new treatment for patients whose blood cancers have returned or not responded to standard therapies. The treatment uses a modified virus that is designed to selectively infect and kill cancer cells while sparing healthy ones. Researchers are st…
Matched conditions: RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Custom immune cells fight blood cancers after transplant
Disease control Recruiting nowThis study tests a personalized immune cell therapy for patients with blood cancers like leukemia, lymphoma, and myeloma. After receiving chemotherapy and a cord blood transplant, patients get infusions of natural killer (NK) cells—immune cells that may kill remaining cancer cell…
Matched conditions: RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control Recruiting nowThis early-stage study is testing a new type of personalized cell therapy for adults with acute myeloid leukemia (AML) that has come back or stopped responding to standard treatments. Doctors take immune cells from a donor, genetically modify them in a lab to better recognize and…
Matched conditions: RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC